Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin E - AbbVie

Next Previous
Drug Profile

Botulinum toxin E - AbbVie

Alternative Names: AGN 151586; Boey; BoNT/E; BoNTE; EB-001; EB-001A; EB-001T; TrenibotE; TrenibotulinumtoxinE

Latest Information Update: 23 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bonti
  • Developer AbbVie
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants; Recombinant proteins; Skin disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents; SNARE protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Glabellar lines
  • Discontinued Musculoskeletal pain; Scars

Most Recent Events

  • 10 Aug 2026 AbbVie initiates a phase I trial for Glabellar lines in USA (IM) (NCT07756580)
  • 10 Aug 2026 AbbVie plans a phase I trial for Glabellar lines in USA (Parenteral, Injection) (NCT07756580)
  • 28 Jul 2026 AbbVie plans a phase II trial for Forehead lines in July 2026 (Parenteral, Injection) (NCT07730554)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top